Benefits
Major depressive disorder + comorbid anxiety (UNPUBLISHED Phase IIa)
BrainCells Inc Phase IIa trial 2010 (BCI-PR-06142010, never peer-reviewed published — press release only) in 101 patients with MDD + GAD comorbidity over 6 weeks randomized double-blind placebo-controlled. Reported: 'depression symptoms of those with co-morbid GAD improved by 12.2 points on HAM-D compared to 5.5 points in the placebo group (p<0.008)'. Began separating from placebo at 4 weeks. Well-tolerated. CRITICAL CAVEATS: never published in peer-reviewed literature, parent company defunct, results known only through press release and archived web materials. Should be interpreted with significant skepticism.
AMPA potentiation + HACU enhancement (bifunctional)
BrainCells described BCI-540 as 'bifunctional molecule that works to treat mood disorders through two mechanisms of action: AMPA potentiation and choline uptake enhancement.' Animal studies confirm both mechanisms. Theoretical basis for combined mood + cognitive effects without acting on serotonin/norepinephrine — relevant for SSRI/SNRI non-responders. Mechanism interesting but clinical translation incomplete due to publication failure.
High-affinity choline uptake (HACU) enhancement — including damaged neurons
Murai 1994 PMID 7710736 (J Neural Transm) demonstrated MKC-231 ameliorates working memory deficits and decreased hippocampal acetylcholine in mice with AF64A-induced cholinergic damage. UNIQUE among racetams: improves choline uptake in DAMAGED neurons (not just healthy). Bessho 1996 PMID 8740080 confirmed water maze learning improvements in rats. Akaike 1998 PMID 9541286 showed protection against glutamate cytotoxicity in cultured cortical neurons. Foundational preclinical evidence.
Phencyclidine-induced deficit antagonism (preclinical)
Shirayama 2007 (Eur Neuropsychopharmacol 17(9):616-626) showed MKC-231 antagonizes phencyclidine-induced behavioral deficits and reduction in septal cholinergic neurons in rats. Theoretical relevance to schizophrenia or NMDA-related cognitive impairment. Mechanism via cholinergic restoration. Preclinical only — no human translation.
Subjective visual/perceptual enhancement (anecdotal)
Users frequently report enhanced color perception, contrast, and visual clarity ('hyper-vivid vision'). Mechanism unclear — possibly cholinergic effects on visual cortex or AMPA modulation effects on sensory processing. Not formally studied in clinical trials. Unique subjective effect among racetams that has driven supplement market interest.
Mechanism of action
High-affinity choline uptake (HACU) enhancement — unique in damaged neurons
Coluracetam selectively enhances HIGH-AFFINITY CHOLINE UPTAKE — rate-limiting step in acetylcholine synthesis. Distinguishing feature from other racetams: improves HACU even in NEURONS WITH DAMAGED CHOLINE TRANSPORT (Murai 1994). Provides theoretical basis for cognitive recovery in pathological states beyond pure enhancement.
AMPA receptor positive modulation
Coluracetam acts as AMPA receptor positive allosteric modulator (similar to aniracetam). Combined with HACU enhancement, provides 'bifunctional' mechanism per BrainCells positioning. Mechanism for proposed mood effects via enhanced glutamatergic-mediated synaptic plasticity and BDNF release.
Glutamate cytotoxicity protection (neuroprotection)
Akaike 1998 demonstrated MKC-231 protects cultured cortical neurons against glutamate cytotoxicity. Mechanism: probably indirect via cholinergic restoration and AMPA modulation reducing excitotoxic damage. Theoretical relevance to ischemia, neurodegeneration.
BBB penetration via lipophilicity
Tetrahydrofuroquinoline structure provides good BBB penetration. Crosses readily; CNS effects achievable at modest doses. Pharmacokinetics less well-characterized than other racetams due to limited published clinical research.
Clinical trials
Phase IIa exploratory trial conducted by BrainCells Inc 2009-2010. Press release only (BCI-PR-06142010); NEVER published in peer-reviewed literature.
101 patients with major depressive disorder (MDD) AND comorbid generalized anxiety disorder (GAD). 6-week randomized double-blind placebo-controlled study. BCI-540 240 mg/day (3x80 mg) vs placebo.
Per press release: depression symptoms in MDD+GAD subgroup improved -12.2 HAM-D points vs -5.5 placebo (p<0.008). Began separating from placebo at 4 weeks. Side effect profile similar to placebo. CRITICAL LIMITATIONS: NEVER published in peer-reviewed literature (~15 years post-trial); parent company BrainCells Inc appears defunct; results known only through archived press release and Wayback Machine. Cannot be verified; should be interpreted with significant skepticism. Demonstrates pattern of orphaned drug candidates with intriguing but unverifiable claims.
Foundational preclinical study (Murai S, Saito H, Abe E, Masuda Y, Odashima J, Itoh T 1994, J Neural Transm Gen Sect 98(1):1-13, doi:10.1007/BF01277590, PMID 7710736).
Mice with AF64A (ethylcholine aziridinium ion)-induced cholinergic neurotoxicity. Working memory deficits and hippocampal acetylcholine measured.
MKC-231 (coluracetam) AMELIORATED working memory deficits and RESTORED decreased hippocampal acetylcholine in cholinergic-damaged mice. UNIQUE FINDING: works in damaged neurons, not just healthy neurons. Foundational preclinical evidence supporting theoretical use in pathological cholinergic states (Alzheimer's, post-injury). Did not translate to successful Mitsubishi AD development.
Preclinical study (Bessho T, Takashina K, Tabata R, Ohshima C, Chaki H, Yamabe H, Egawa M, Tobe A, Saito K 1996, Arzneimittelforschung 46(4):369-373, PMID 8740080).
Rats with experimentally induced learning deficits. Water maze (Morris) navigation learning measured with MKC-231 treatment.
MKC-231 IMPROVED water maze learning deficits in rats. Effects observed at low doses without obvious side effects. Tacrine (control AChEI) at 0.1-3 mg/kg p.o. FAILED to ameliorate same deficits — distinguishing MKC-231's mechanism. Authors concluded: 'MKC-231 is a novel and quite unique compound, which improves the memory impairment induced by AF64A through the enhancement of HACU without any side effects at the effective doses.' Solid preclinical foundation.
About this ingredient
Coluracetam (BCI-540, formerly MKC-231; chemical name 2-(2-oxopyrrolidin-1-yl)-N-(2,3-dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl)acetamide) is a tetrahydrofuro-quinoline-pyrrolidone hybrid — STRUCTURALLY DIFFERENT from typical racetams. Contains a chemical group that is bioisostere of 9-amino-tetrahydroacridine (tacrine) family. INITIALLY DEVELOPED by Mitsubishi Tanabe Pharma Corporation in Japan (mid-1990s) as MKC-231 for Alzheimer's disease — failed Phase II clinical endpoints.
IN-LICENSED 2006 by BrainCells Inc (San Diego) and rebranded BCI-540 for major depressive disorder with comorbid generalized anxiety disorder. Phase IIa trial in 101 patients (2009-2010) reportedly showed substantial benefit in MDD+GAD subgroup (HAM-D -12.2 vs -5.5 placebo, p<0.008) per press release — NEVER PUBLISHED in peer-reviewed literature. BrainCells Inc subsequently appears defunct.
UNIQUE PHARMACOLOGY: HIGH-AFFINITY CHOLINE UPTAKE (HACU) ENHANCER that works EVEN IN NEURONS WITH DAMAGED CHOLINE TRANSPORT (Murai 1994 — distinguishing it from typical cognitive enhancers that need healthy substrate). Combined with AMPA RECEPTOR POSITIVE MODULATION makes it a 'bifunctional' molecule per BrainCells positioning. PRECLINICAL EVIDENCE BASE: Murai 1994 PMID 7710736 (HACU restoration in cholinergic-damaged mice), Bessho 1996 PMID 8740080 (water maze learning improvements), Akaike 1998 PMID 9541286 (glutamate cytotoxicity protection), Shirayama 2007 (PCP-induced deficit antagonism).
REGULATORY STATUS: never approved anywhere. Sold as 'research compound' / nootropic supplement in US (gray zone). Unique subjective effects often reported by users include enhanced color perception, contrast, and visual clarity ('hyper-vivid vision') — mechanism unclear, not formally studied.
EVIDENCE: 1/5 reflects: (1) FAILED Mitsubishi AD development, (2) UNPUBLISHED BrainCells Phase IIa MDD+GAD trial (only press release 2010 — significant credibility concern), (3) defunct parent company, (4) solid preclinical evidence (Murai, Bessho, Akaike) but no peer-reviewed human RCTs, (5) unique HACU mechanism with theoretical importance, (6) limited long-term safety data, (7) gray regulatory status in US. SAFETY: Generally well-tolerated based on limited data; long-term safety not adequately characterized. Best positioned as: (a) NOT recommended for general use based on absence of peer-reviewed human RCT evidence, (b) MOST ORPHANED of major racetams — pharmaceutical abandonment by both Mitsubishi (AD) and BrainCells (MDD), (c) RESEARCH COMPOUND status in US warrants significant regulatory caution, (d) interesting preclinical mechanism (unique HACU restoration in damaged neurons) but clinical translation failed, (e) example of supplement market promoting unverifiable claims based on press release rather than peer-reviewed evidence.
Honest framing: coluracetam is the most evidentially-weak racetam due to BrainCells Phase IIa never being peer-review published. The 'studies' driving supplement marketing trace back to a 2010 press release from a now-defunct company. Solid preclinical mechanism but rigorous human evidence is absent.
Reasonable preclinical interest in HACU restoration mechanism for future research; not currently recommended for clinical or nootropic use based on rigor of available evidence.